Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trialDavid Marín, Katayoun Rezvani, Ken Chen et al.|Nature Medicine|2024Cited by 452
Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDSMarcos de Lima, Börje S. Andersson, Daniel R. Couriel et al.|Blood|2004Cited by 422
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapyKris M. Mahadeo, Sajad Khazal, Hisham Abdel‐Azim et al.|Nature Reviews Clinical Oncology|2018Cited by 236
A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapyChristoph K. Stein‐Thoeringer, Eran Elinav, Neeraj Saini et al.|Nature Medicine|2023Cited by 226
Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphomaPaolo Strati, Sattva S. Neelapu, Sairah Ahmed et al.|Blood|2021Cited by 213